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OBJECTIVE—We sought to determine whether insulin resistance predicts the incidence and
progression of coronary artery calcification (CAC).
RESEARCH DESIGN AND METHODS—We studied 5,464 participants not on hypo-
glycemic therapy from the Multi-Ethnic Study of Atherosclerosis (MESA). Each had baseline
homeostasis model assessment of insulin resistance (HOMA-IR) and baseline and follow-upCAC
scores. Incident CAC was defined as newly detectable CAC; progression was defined as advancing
CAC volume score at follow-up.
RESULTS—Median HOMA-IR was 1.2 (0.8–2.0). Across all ethnicities, there was a graded
increase in CAC incidence and progression with increasing HOMA-IR. When compared with
those in the 1st quartile, participants in the 2nd–4th quartiles had 1.2, 1.5, and 1.8 times greater
risk of developing CAC. Median annualized CAC score progression was 8, 14, and 17 higher,
respectively. However, HOMA-IR was not predictive after adjustment for metabolic syndrome
components.
CONCLUSIONS—HOMA-IR predicts CAC incidence and progression, but not indepen-
dently of metabolic syndrome.
Diabetes Care 34:749–751, 2011
Sensitivity to insulin-mediated glu-cose uptake varies at least sixfold inthe general healthy population, with
variability attributable to genetic and
behavioral factors (1–4). In the clinical
setting, insulin resistance is commonly in-
ferred via its adverse consequences,
which include dysglycemia, hyperten-
sion, low HDL cholesterol (HDL-C), high
triglycerides, and subclinical inflamma-
tion (collectively, the metabolic syndrome)
(5).
Insulin resistance and the metabolic
syndrome have both been shown to be
strongly associated with measures of sub-
clinical atherosclerosis, including coro-
nary artery calcification (CAC) (6,7).
Consistent with these observations, pro-
spective studies have demonstrated that
insulin resistance and metabolic syn-
drome are independent predictors of car-
diovascular events (8,9). However, the
degree to which insulin resistance and
metabolic syndrome are mutually inde-
pendent predictors remains debated,
with prior results mixed (7,10). We
sought to determine whether insulin re-
sistance prospectively predicts the onset
and progression of CAC, independent of
metabolic syndrome.
RESEARCH DESIGN AND
METHODS—The Multi-Ethnic Study
of Atherosclerosis (MESA) enrolled 6,814
men and women of four ethnicities
(white, Chinese, African American, and
Hispanic) into a population-based study
aimed at describing the prevalence, pro-
gression, and significance of subclinical
atherosclerosis (11). Patients were aged
45–84 without known cardiovascular
disease. We excluded participants with
no baseline assessment of insulin resis-
tance (N = 32) and no follow-up CAC
scans (N = 768) and/or who were treated
with hypoglycemic therapy (N = 678),
for a final population of 5,464 partici-
pants (2,284 whites; 638 Chinese; 1,411
African Americans; and 1,131 Hispanics).
Baseline insulin resistance was de-
fined as homeostasis model assessment
of insulin resistance (HOMA-IR), calcu-
lated as fasting insulin [mU/mL]3 fasting
glucose [mg/dL]/405 (MESA 2000–
2002). Serum glucose was measured by
the Vitros analyzer (Johnson & Johnson
Clinical Diagnostics) and insulin by ra-
dioimmunoassay using the Linco Human
Insulin Specific RIA kit (Linco Research).
Metabolic syndrome was identified using
the modified NCEP ATPIII definition.
Baseline cardiac computed tomography
was performed twice on all participants,
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with CAC scores averaged. A second CAC
measurement was performed on one-half
of the cohort at exam 2, and the other half
at exam 3, an average of 1.6 and 3.2 years
after baseline (MESA 2002–2005). CAC
incidence was defined as any detectable
CAC in individuals without CAC at base-
line. CAC progression was defined as ad-
vancing CAC volume score in participants
with detectable baseline CAC.
In separate models, we assessed the
multivariable-adjusted relationship of
HOMA-IR (quartiles and continuous)
with CAC incidence and CAC progres-
sion. For CAC incidence, we calculated
relative risks using a generalized estimat-
ing equation with log link and binomial
distribution. For CAC progression, we
calculated b-coefficients (units = change
in CAC volume score/year) using robust
linear regression.
RESULTS—The mean age of the pop-
ulation was 62 6 10, and 53% were
women. Median HOMA-IR was 1.2
(0.8–2.0). There was a graded association
between increasing HOMA-IR and male
sex, African American and Hispanic eth-
nicity, BMI, untreated diabetes, HDL-C,
and triglycerides (all P , 0.01). At base-
line, 47% of patients had CAC, with a
mean volume score of 230 and median
volume score of 76 (22–252).
There was a graded association be-
tween HOMA-IR quartile and CAC in-
cidence. The rate of incident CAC for the
1st through 4th quartiles was 4.4, 5.4,
6.8, and 7.8 per 100 person-years. Ad-
justed for age, sex, ethnicity, MESA site,
and years in between scans, participants
in the 2nd–4th quartiles were 1.2, 1.5,
and 1.8 times more likely to develop
CAC comparedwith those in the 1st quar-
tile. Strong associations persisted for all
but Hispanics. However, HOMA-IR was
no longer predictive after adjusting for
metabolic syndrome components and
other established risk factors (Table 1).
There was also a graded association
between HOMA-IR quartile and CAC
progression. Median annualized CAC
volume score progression for the 1st
through the 4th quartiles was 37, 45,
51, and 55 per year. When compared
with the 1st quartile, incremental median
annualized CAC score progression was 8,
14, and 17 higher, respectively. Inmodels
adjusted for age, sex, ethnicity, MESA
site, years in between scans, and log
(baseline CAC), there were significantly
increased CAC progression rates for the
3rd (b = 9.4, 95% CI 2.2–16.6) and 4th
(b = 11.5, 95% CI 4.5–18.4) quartiles
compared with the 1st quartile. This as-
sociation was the strongest among whites.
However, there was no association after
adjusting for metabolic syndrome com-
ponents or established risk factors
(Table 1).
As a continuous variable, HOMA-IR
predicted CAC incidence and progression
but was not predictive after adjustment
for metabolic syndrome components.
Each individual component, except for
low HDL-C, predicted CAC incidence
and progression. HOMA-IR remained
predictive in models adjusting for indi-
vidual components, without evidence of
interaction. Normal weight/insulin resis-
tant and obese/insulin sensitive individu-
als had similar risk of incident CAC; the
joint risk with both obesity and insulin
resistance was merely additive, without
interaction. The results of this study were
not changed when participants with un-
treated diabetes were excluded.
CONCLUSIONS—We demonstrate
that insulin resistance measured by
HOMA-IR predicts CAC incidence and
progression, which are established pre-
dictors of adverse events (12), but not in-
dependently of metabolic syndrome
components. This suggests that although
insulin resistance is an important patho-
biologic contributor to coronary artery
disease, it does not add additional predic-
tive value beyond routine risk assessment.
Mechanistically, insulin resistance
lies upstream of the metabolic syndrome
and its consequences on the causal path-
way for cardiovascular disease. Thus it is
less surprising that the predictive value
of HOMA-IR is attenuated after multi-
variable adjustment. Indeed, the meta-
bolic syndrome and its components are
independently associated with subclinical
atherosclerosis and adverse cardiovascu-
lar outcomes (6–9). Recently microalbu-
minuria, which has been viewed as both a
consequence or a defining feature of met-
abolic syndrome (13), has been shown to
predict CAC progression (14). Although
debated (8,10), our study argues against
routine clinical measurement of HOMA-
IR but supports identification of the
Table 1—HOMA quartile (4th vs. 1st) for the prediction of CAC incidence and
progression in MESA
HOMA 4th quartile vs. HOMA 1st quartile
Incident CAC
Relative risk (95% CI)
CAC progression†
DCAC score (95% CI)
Total population
Model 1 1.78 (1.43–2.22)** 11.5 (4.5–18.4)**
Model 2 1.21 (0.92–1.61) 23.0 (211.8 to 5.8)
Model 3 1.02 (0.77–1.35) 20.9 (210.2 to 8.5)
White
Model 1 1.62 (1.15–2.28)** 13.6 (1.3–26.0)*
Model 2 1.03 (0.66–1.60) 28.3 (224.2 to 7.6)
Model 3 0.86 (0.57–1.29) 21.2 (218.2 to 15.9)
Chinese
Model 1 3.24 (1.18–8.90)* 8.4 (26.6 to 23.5)
Model 2 2.98 (0.35–25.7) 2.3 (222.0 to 12.7)
Model 3 2.49 (0.34–18.4) 21.4 (221.9 to 19.0)
African American
Model 1 1.81 (1.19–2.75)* 9.5 (24.7 to 23.6)
Model 2 1.08 (0.59–1.98) 24.7 (218.2 to 14.5)
Model 3 0.92 (0.50–1.72) 22.1 (220.8 to 16.6)
Hispanic
Model 1 1.51 (0.86–2.65) 7.7 (26.4 to 21.7)
Model 2 1.32 (0.64–2.74) 21.5 (219.0 to 16.1)
Model 3 0.93 (0.44–2.00) 24.8 (223.6 to 14.0)
HOMA quartiles: 1st quartile (0.14–0.79), 2nd quartile (0.80–1.24), 3rd quartile (1.24–2.03), 4th quartile
(.2.03). Model 1, adjusted for age, sex, ethnicity, MESA site, and years between CAC scans; Model 2, Model
1 + NCEP ATPIII metabolic syndrome components (waist circumference, impaired fasting glucose, lowHDL-
C, high triglycerides, and hypertension [categorical]); and Model 3, Model 1 + NCEP ATPII metabolic
syndrome components (continuous) except for impaired fasting glucose (categorical), diabetes, smoking,
LDL-C, family history of coronary heart disease, and cholesterol-lowering medications. †Additionally ad-
justed for log (baseline CAC) in the CAC progression model. *P , 0.05; **P , 0.005.
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metabolic syndrome and measurement of
its component risk factors.
Our study adds to a prior study by Lee
et al. (15) that demonstrated an indepen-
dent association between fasting insulin,
but not HOMA-IR, and CAC progression.
This smaller study (869 patients) of an
older (mean age 66 years), more homog-
enous population had several limitations.
First, the study was likely underpowered.
Second, this study examined progression
of CAC score and did not separately
model incident CAC. Finally, plasma in-
sulin values were used, which are notori-
ously variable and of limited use when not
accounting for plasma glucose (as in
HOMA-IR).
In conclusion, insulin resistance pre-
dicts CAC incidence and progression in
all four ethnicities. However, clinical
identification of the metabolic syndrome
and measurement of its associated risk
factors is preferred over HOMA-IR for
predicting coronary atherosclerosis.
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